Presentation is loading. Please wait.

Presentation is loading. Please wait.

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response  Meri K Tulic, PhD, Pierre-Olivier Fiset,

Published byBjörn Berg Modified over 5 years ago

Similar presentations

Presentation on theme: "Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response  Meri K Tulic, PhD, Pierre-Olivier Fiset,"— Presentation transcript:

1 Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response  Meri K Tulic, PhD, Pierre-Olivier Fiset, BSc, Pota Christodoulopoulos, PhD, Patrice Vaillancourt, MSc, Martin Desrosiers, MD, François Lavigne, MD, Joseph Eiden, MD, Qutayba Hamid, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 113, Issue 2, Pages (February 2004) DOI: /j.jaci

2 FIG 1 Dosing schedule for AIC immunotherapy in ragweed-sensitive patients. AIC (or placebo) was administered once per week for 6 weeks before ragweed season nasal biopsy specimens were taken 24 hours after allergen challenge for evaluation of the late-phase response. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

3 FIG 2 Effect of AIC on allergen challenge before the ragweed season. The number of MBP-positive cells (A), IL-5 mRNA–positive cells (B), IL-4 mRNA–positive cells (C), and IFN-γ mRNA–positive cells (D) at baseline (B) and after nasal allergen challenge with ragweed extract (A) in ragweed-sensitive patients 2 weeks after treatment with placebo (n = 7) or AIC (n = 12) is shown. Circles alongside the data represent mean values ± SEM. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

4 FIG 3 Effect of AIC on allergen challenge after the ragweed season. The number of MBP-positive cells (A), IL-5 mRNA–positive cells (B), IL-4 mRNA–positive cells (C), and IFN-γ mRNA–positive cells (D) at baseline (B) and after nasal allergen challenge with ragweed extract (A) in ragweed-sensitive patients 4 to 5 months after treatment with placebo (n = 7) or AIC (n = 12) is shown. Circles alongside the data represent mean values ± SEM. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

5 FIG 4 Clinical efficacy of AIC in ragweed-sensitive subjects. The least square means of daily nasal (A) and chest (B) symptom scores are shown for the entire ragweed-pollen season. Data are calculated as the change from preseason baseline symptom scores. Periods corresponding to the 4-week period of maximum pollen counts and the 2-week period of maximum total symptom scores are shown. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

Download ppt "Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response  Meri K Tulic, PhD, Pierre-Olivier Fiset,"

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.
Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.

Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses  Chris J. Corrigan, MD, PhD, Wei.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine  Alina F. Dumitru, MD, Mohamed.
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,
Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy.

Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment  Laura Van Gerven, MD, PhD, Yeranddy.
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge  Yee Ean Ong, MBBS, Andrew Menzies-Gow,

Similar presentations

Ads by Google